Benefits
Appetite suppression and hunger reduction
Slendesta® PI2 stimulates CCK (cholecystokinin) release from intestinal I-cells — the primary gut satiety hormone that signals fullness to the brain via vagal nerve afferents. Multiple clinical studies show significantly reduced hunger scores, decreased desire to eat, and improved satiety in adults taking Slendesta® before meals.
Caloric intake and meal size reduction
In a lab-meal study, oral PI2 reduced energy intake (Hill 1990), and an RCT in healthy women found PI2 suppressed postprandial appetite versus placebo (Zhu 2017). These findings support a satiety-mediated reduction in food intake, though the magnitude of any effect in everyday use has not been reliably quantified.
Body weight management
The only controlled weight-outcome RCT of potato PI2 (Flechtner-Mors 2020, n=52, 20 weeks, on a 500 kcal-deficit diet) found no significant weight-loss advantage for PI2 over placebo (PI2 lost 5.6 kg vs 6.8 kg in control). Slendesta's demonstrated human effects are on satiety and appetite, which are surrogate measures. A controlled weight-loss advantage over placebo has not been established.
Blood sugar and insulin response modulation
CCK stimulation can slow gastric emptying, which is a proposed mechanism for more gradual glucose absorption. This is a theoretical, mechanism-level consideration; no human glycemic outcome has been demonstrated for Slendesta in the cited studies.
Mechanism of action
CCK (cholecystokinin) release stimulation
PI2 inhibits luminal trypsin and chymotrypsin in the small intestine, triggering release of CCK-releasing factor (CCKLF) from intestinal mucosal cells. CCKLF then stimulates I-cells to secrete CCK into the bloodstream. CCK activates CCK-A receptors on vagal nerve afferents, transmitting satiety signals to the hypothalamic satiety center, reducing meal size and duration.
Gastric emptying delay
CCK released in response to Slendesta® PI2 contracts the pyloric sphincter and slows gastric emptying, extending the duration of gastric distension and prolonging the gastric satiety signal. This delayed gastric emptying may also produce more gradual glucose absorption, a proposed effect not demonstrated as a clinical glycemic benefit for Slendesta.
Hypothalamic appetite center modulation
CCK-A receptor activation in the nucleus tractus solitarius (NTS) of the brainstem activates satiety-promoting neurons in the hypothalamic arcuate nucleus, reducing orexigenic NPY/AgRP neuron activity and increasing anorexigenic POMC neuron signaling — creating a physiological state of genuine satiety.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 52 overweight/obese adults over 20 weeks. Both groups followed a protein-rich 500 kcal-deficit diet; the PI2 group took 150 mg PI2 twice daily before lunch and dinner.
52 overweight/obese adults (BMI 25.2–38.0 kg/m²). Randomized, placebo-controlled trial over 20 weeks. Subjects on protein-rich diet (30%) at 500 kcal deficit. PI2 group: 150 mg PI2 twice daily, 1 hour before lunch and dinner.
PI2 increased circulating CCK and improved satiety/appetite ratings from week 4 through week 20 versus placebo. However, weight loss did not differ significantly between groups (PI2 5.6 kg vs control 6.8 kg at week 20), so PI2 provided no weight-loss advantage over placebo. The demonstrated effects were on CCK and satiety, not on superior weight loss.
Randomized double-blind placebo-controlled trial (n=44 healthy women) measuring postprandial appetite after PI2 vs placebo. (Zhu 2017)
44 healthy women.
In a randomized, double-blind, placebo-controlled trial in 44 healthy women (Zhu 2017), PI2 significantly suppressed postprandial appetite versus placebo. Appetite here is a self-reported surrogate measure; this study did not demonstrate weight loss.